These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11704311)

  • 21. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-small cell lung cancer: the role of cytoprotection in treating therapy-related toxicity.
    Gopal R
    J Support Oncol; 2004; 2(6 Suppl 3):13-7. PubMed ID: 15605920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.
    Gopal R
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S55-9. PubMed ID: 16015536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
    Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
    Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
    Small W; Winter K; Levenback C; Iyer R; Hymes SR; Jhingran A; Gaffney D; Erickson B; Greven K
    Int J Gynecol Cancer; 2011 Oct; 21(7):1266-75. PubMed ID: 21892091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
    Gridelli C; Guida C; Barletta E; Gatani T; Fiore F; Barzelloni ML; Rossi A; de Bellis M; D'Aniello R; Scognamiglio F
    Lung Cancer; 2000 Aug; 29(2):131-7. PubMed ID: 10963843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial.
    Athanassiou H; Antonadou D; Coliarakis N; Kouveli A; Synodinou M; Paraskevaidis M; Sarris G; Georgakopoulos GR; Panousaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1154-60. PubMed ID: 12829154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
    Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of amifostine on locally advanced non-small cell lung cancer patients treated with radiotherapy: a meta-analysis of randomized controlled trials].
    Wang S; Zhang Y; Zhang S; Ma S
    Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):539-44. PubMed ID: 22989457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
    Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
    Werner-Wasik M; Axelrod RS; Friedland DP; Hauck W; Rose LJ; Chapman AE; Grubbs S; Deshields M; Curran WJ
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):34-9. PubMed ID: 11917282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between local dose and loss of function for irradiated lung.
    Gopal R; Tucker SL; Komaki R; Liao Z; Forster KM; Stevens C; Kelly JF; Starkschall G
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):106-13. PubMed ID: 12694828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction).
    Valeriani M; Marinelli L; Nicosia L; Reverberi C; De Sanctis V; Mollo D; Osti MF
    Radiol Med; 2019 Dec; 124(12):1324-1332. PubMed ID: 31317381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.
    Wurstbauer K; Deutschmann H; Kranzinger M; Merz F; Rahim H; Sedlmayer F; Kogelnik HD
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):333-41. PubMed ID: 10760428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
    Garces YI; Okuno SH; Schild SE; Mandrekar SJ; Bot BM; Martens JM; Wender DB; Soori GS; Moore DF; Kozelsky TF; Jett JR
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):995-1001. PubMed ID: 17336213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.